Oncimmune Holdings plc
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
Oncimmune Holdings plc (ONC) - Total Liabilities
Latest total liabilities as of August 2024: GBX7.30 Million GBX
Based on the latest financial reports, Oncimmune Holdings plc (ONC) has total liabilities worth GBX7.30 Million GBX as of August 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncimmune Holdings plc - Total Liabilities Trend (2012–2024)
This chart illustrates how Oncimmune Holdings plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncimmune Holdings plc Competitors by Total Liabilities
The table below lists competitors of Oncimmune Holdings plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Big Gold Inc.
F:H7L
|
Germany | €270.41K |
|
Euro-Med Laboratories Phils Inc
PSE:EURO
|
Philippines | ₱4.35 Billion |
|
RISANAMENTO
MU:RN5
|
Germany | €136.32 Million |
|
Alsons Consolidated Resources Inc
PSE:ACR
|
Philippines | ₱34.74 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Oncimmune Holdings plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncimmune Holdings plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncimmune Holdings plc (2012–2024)
The table below shows the annual total liabilities of Oncimmune Holdings plc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-08-31 | GBX7.30 Million | -6.14% |
| 2023-08-31 | GBX7.78 Million | -61.07% |
| 2022-05-31 | GBX19.98 Million | +4.90% |
| 2021-05-31 | GBX19.05 Million | +81.28% |
| 2020-05-31 | GBX10.51 Million | +571.07% |
| 2019-05-31 | GBX1.57 Million | +84.45% |
| 2018-05-31 | GBX849.00K | -39.49% |
| 2017-05-31 | GBX1.40 Million | -5.01% |
| 2016-05-31 | GBX1.48 Million | -74.40% |
| 2015-05-31 | GBX5.77 Million | +32.34% |
| 2014-05-31 | GBX4.36 Million | +83.27% |
| 2013-05-31 | GBX2.38 Million | +20.70% |
| 2012-05-31 | GBX1.97 Million | -- |